EP Patent

EP2702173A1 — Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment

Assigned to Aveo Pharmaceuticals Inc · Expires 2014-03-05 · 12y expired

What this patent protects

The present invention provides diagnostic methods for assessing the EMT status of tumor cells, and for predicting the effectiveness of treatment of a cancer patient with an EGFR or IGF-1R kinase inhibitor, utilizing an EMT gene signature index score. The present invention further…

USPTO Abstract

The present invention provides diagnostic methods for assessing the EMT status of tumor cells, and for predicting the effectiveness of treatment of a cancer patient with an EGFR or IGF-1R kinase inhibitor, utilizing an EMT gene signature index score. The present invention further provides methods for treating patients with cancer that incorporate these methods.

Drugs covered by this patent

Patent Metadata

Patent number
EP2702173A1
Jurisdiction
EP
Classification
—
Expires
2014-03-05
Drug substance claim
No
Drug product claim
No
Assignee
Aveo Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.